Nkarta (NKTX) Return on Capital Employed (2020 - 2026)
Nkarta's quarterly Return on Capital Employed came in at 31.44% in Q1 2026, down 318.0% year-on-year from 14.42% in Q1 2025, and down 1.4% quarter-over-quarter from 31.01% in Q4 2025.
Nkarta has reported Return on Capital Employed for 7 years, with the latest figure at 31.44% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 318.0% year-over-year to 31.44%; the trailing twelve-month figure through Mar 2026 stood at 31.44% (down 318.0% YoY), and the FY2025 full-year result was 28.34%, up 210.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 31.44%, down from 31.01% in the prior quarter.
- The five-year high for Return on Capital Employed was 22.39% in Q3 2022, with the low at 35.67% in Q4 2023.
- Average Return on Capital Employed over 5 years is 28.77%, with a median of 28.93% recorded in 2023.
- Year-over-year, Return on Capital Employed tumbled 1421 bps in 2022 and soared 996 bps in 2024.
- Tracing NKTX's Return on Capital Employed over 5 years: stood at 25.51% in 2022, then sank by 40 bps to 35.67% in 2023, then advanced by 28 bps to 25.76% in 2024, then decreased by 20 bps to 31.01% in 2025, then retreated by 1 bps to 31.44% in 2026.
- The last three Return on Capital Employed figures came in at 31.44% (Q1 2026), 31.01% (Q4 2025), and 29.12% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -31.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.44% |
| Dec 31, 2025 | -31.01% |
| Sep 30, 2025 | -29.12% |
| Jun 30, 2025 | -29.16% |
| Mar 31, 2025 | -28.26% |
| Dec 31, 2024 | -25.76% |
| Sep 30, 2024 | -24.67% |
| Jun 30, 2024 | -22.76% |
| Mar 31, 2024 | -28.55% |
| Dec 31, 2023 | -35.67% |
| Sep 30, 2023 | -34.57% |
| Jun 30, 2023 | -32.71% |
| Mar 31, 2023 | -28.93% |
| Dec 31, 2022 | -25.51% |
| Sep 30, 2022 | -22.39% |
| Jun 30, 2022 | -25.28% |
| Mar 31, 2022 | -33.32% |
| Dec 31, 2021 | -31.98% |
| Sep 30, 2021 | -28.24% |
| Jun 30, 2021 | -23.72% |
| Mar 31, 2021 | -19.11% |
| Dec 31, 2020 | -15.32% |
| Sep 30, 2020 | -22.38% |